Indication
In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Medicine details
- Medicine name:
- acalabrutinib (Calquence)
- SMC ID:
- SMC2893
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 13 April 2026